Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. - Wikidata - awgldk - TriplyDB

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.

http://www.wikidata.org/entity/Q37818248

about

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.Acute myeloid leukemia stem cells and CD33-targeted immunotherapy Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin Antibody-drug conjugates - a perfect synergy.Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.Immunotherapeutic approaches for cancer therapy: An updated review.Update on antigen-specific immunotherapy of acute myeloid leukemia.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.Gemtuzumab ozogamicin in acute myeloid leukemia.Frontline treatment of acute myeloid leukemia in adults.The development of targeted new agents to improve the outcome for children with leukemia.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

P2860

Q35146288-78961DA7-1863-4D3B-BC82-7C4B5B213CEA Q35266020-CBB9F713-C2EA-4202-8D5B-079F30E9A74F Q36058588-5092AABA-203F-4157-BAC6-86E8516C9161 Q36932014-4DF955D4-1362-4701-9BCA-02A2079766FA Q38014923-8F6DEFE8-7310-416A-882A-4561F18972FC Q38106032-3B0A6C25-38F4-47B3-9AE8-D831F860BD58 Q38388102-54757DB8-94B4-4515-BCB6-B5C17E768D0D Q38432103-2825FF67-4BDA-435F-99F8-706439B7530A Q38707852-17265B76-630F-4F48-B62D-66A1A9487C8E Q38728718-BC7D50DA-C8CF-41C5-82B1-B6FA2FC60C93 Q38767583-75CDB71B-5297-4B51-9B50-19051E6694BC Q38964974-F077C7B6-209D-44DF-A253-50D7750BF0EB Q47221234-94A5EB49-DADC-46E2-AC43-17E73037F927

P2860

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.

http://www.wikidata.org/entity/Q37818248

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 December 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Gemtuzumab ozogamicin for the ...... sistance, safety and efficacy.

@en

Gemtuzumab ozogamicin for the ...... sistance, safety and efficacy.

@nl

type

label

Gemtuzumab ozogamicin for the ...... sistance, safety and efficacy.

@en

Gemtuzumab ozogamicin for the ...... sistance, safety and efficacy.

@nl

prefLabel

Gemtuzumab ozogamicin for the ...... sistance, safety and efficacy.

@en

Gemtuzumab ozogamicin for the ...... sistance, safety and efficacy.

@nl

P1433

Q37818248-5E1301C8-44A8-45B9-B621-6BAB08743E2E

P1476

Q37818248-04AA6756-5D98-4AD9-9225-6FDE387E3DC0

P2860

Q37818248-03C33FEC-D1F2-476C-B864-54DFF5AFBAF9

Q37818248-085C81E7-7894-4D31-B149-AA38D77DC18B

Q37818248-08E03687-9C1B-4463-B4E2-DC240D71C992

Q37818248-15A399CF-602F-457F-9358-F3B62EE8368A

Q37818248-18385052-63AA-434C-82D8-85DD7F264C1D

Q37818248-18A4FBFF-133D-4AD3-BA18-9DA69485CAC8

Q37818248-1A4FC32D-BC10-45BB-A4E8-C699557050A6

Q37818248-1A8B504D-5B04-4939-9F69-DDB1817F3E31

Q37818248-20A47FC9-1DDC-4CF0-81E5-69EB9D5909BA

Q37818248-24783288-68B8-49E7-BFCB-D6DC5B734F6D

P304

Q37818248-588E9FD5-243A-48BE-80B4-D8DEBC65E4B6

P31

Q37818248-6CC126FA-C7C5-4E92-8550-5506AFE79ABA

Q37818248-9cddf956-1826-4fec-8e5e-ddd7302f2dcb

P356

Q37818248-7BD5D277-C759-4FF9-B550-2FBE99F64F72

P407

Q37818248-D13D5A63-69FD-4294-A36B-9E16F6EAA47E

P433

Q37818248-7499DBC0-98A2-41DE-8043-256F401BEAD6

P478

Q37818248-261576F1-242F-408D-8547-E6D1C0DA66E5

P50

Q37818248-8A21F960-EC53-42E4-9CDB-33B51A3CF0C0

Q37818248-D47FFB54-B6AA-438A-A752-31F0DA2B0D93

P577

Q37818248-5057C036-7FCC-4EAB-A612-A6215FE19624

P698

Q37818248-C864FBA2-B0F1-4739-95D0-B097A1503FBF

P921

Q37818248-71D62907-576E-47B2-90E2-E63F565BDAD3

P356

14712598.2011.543895

P1433

Expert Opinion on Biological Therapy

P1476

Gemtuzumab ozogamicin for the ...... sistance, safety and efficacy.

@en

P2860

The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

Solution structure of the calicheamicin gamma 1I-DNA complex

Molecular pathogenesis of acute promyelocytic leukaemia and APL variants

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

Acute promyelocytic leukemia: evolving therapeutic strategies.

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

P304

225-234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2011.543895

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Breccia

Francesco Lo-Coco

P577

2010-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21142804

http://www.w3.org/2001/XMLSchema#string

P921